Regeneron: 3 Key Takeaways for Long-Term Investors

Regeneron reported third-quarter 2026 revenue of $5.1 billion, up 36% year over year. Sanofi-reported Dupixent global sales reached a record $6.5 billion, up 35% at constant currency, while U.S. EYLEA HD sales rose 62% to $699 million. An early CIDEB-targeting siRNA trial in 40 participants showed an average 70% reduction in liver fat after 12 weeks; Regeneron plans to increase 2027 research spending by a mid-teens percentage to support 15 late-stage trials and also cited share repurchases.

Analysis

The key investment distinction is between franchise momentum and what REGN actually captures economically. Sanofi-reported Dupixent sales should not be treated as REGN revenue: the alliance’s revised cost-sharing and development terms could change future economics, but the article gives no detail on the split. Verify REGN’s recognized collaboration revenue and profit-sharing disclosures before extrapolating the product’s growth to consolidated earnings.

For EYLEA, HD uptake is evidence of a transition, not yet proof that the franchise is insulated from competition. The decisive measure is whether HD growth offsets declines in the original formulation in total franchise revenue, with unit share and net pricing holding up against alternatives such as Roche’s Vabysmo. If substitution is mainly within REGN’s own portfolio, the benefit may be mix and durability rather than incremental market growth.

The CIDEB result is an option, not a valuation anchor: a small early study’s liver-fat reduction does not establish improvement in clinical outcomes or regulatory success. The mid-teens R&D increase planned for 2027 also creates a near-term cash-flow headwind before any pipeline payoff. The sharp positive market reaction raises the bar for follow-through; without valuation and estimate-revision data, the move’s cheapness cannot be assessed.

Over 1–3 months, track total EYLEA franchise sales, Dupixent economics disclosed by REGN, and subsequent clinical updates. Over 6–18 months, successful late-stage programs could leverage existing commercial infrastructure, but trial failures or weaker-than-expected returns on higher R&D would challenge that thesis.

Key Decisions for Investors

• Avoid chasing the immediate REGN move. Consider adding only after price consolidation and confirmation that analyst estimates—not just the narrative—are moving higher; valuation and revised earnings expectations are needed before sizing a position.
• Set an alert for REGN’s next disclosure of total EYLEA franchise sales, HD unit share, and net pricing. Falsification: HD gains fail to offset erosion in the original formulation or share/pricing deteriorates against Vabysmo.
• Do not capitalize the CIDEB biomarker result as near-term earnings. Reassess only with larger, longer-duration data tied to clinically meaningful outcomes; lack of follow-up efficacy or tolerability would remove this pipeline optionality.
• Monitor the 2027 R&D increase against pipeline progress and cash generation. If spending rises while late-stage milestones slip or guidance weakens, reduce exposure; if milestones advance without deterioration in cash-flow outlook, the commercial-platform thesis strengthens.
• Before attributing Dupixent growth to REGN, verify the alliance’s updated economics and REGN-recognized revenue. The Sanofi-reported product sales figure alone is not a sufficient basis for a REGN earnings estimate.